Document is current
Any future updates will be listed below
-
Authors
Yang, Yang https://orcid.org/0000-0003-3801-681X
Jn-Simon, Natacha https://orcid.org/0009-0006-6533-2569
He, Yonghan https://orcid.org/0000-0003-4409-4590
Sun, Chunbao
Zhang, Peiyi
Hu, Wanyi
Tian, Tian
Zeng, Huadong
Basha, Sreenivasulu
Huerta, Araceli S.
Sun, Lu-Zhe
Yin, Xian-Ming https://orcid.org/0000-0002-8576-6093
Hromas, Robert
Zheng, Guangrong https://orcid.org/0000-0002-8106-6663
Pi, Liya https://orcid.org/0000-0002-9868-7677
Zhou, Daohong https://orcid.org/0000-0002-2400-6461
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 AG063801)
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA242003)
U.S. Department of Health & Human Services | National Institutes of Health (P30 CA054174)
U.S. Department of Health & Human Services | National Institutes of Health (R01 AG063801)
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA242003)
U.S. Department of Health & Human Services | National Institutes of Health (K01 AA024174)
U.S. Department of Health & Human Services | National Institutes of Health (R01 AA028035)
Cancer Prevention and Research Institute of Texas (RP210208)
United States Department of Commerce | National Institute of Standards and Technology (60NANB24D117)
- License Information
-
More Information
Article History
Received: 2 March 2023
Accepted: 5 December 2024
First Online: 31 January 2025
Competing interests
: Y.Y., Y.H., P.Z., W.H., G.Z., L.P. and D.Z. are inventors on patents for the use of BCL-xL PROTACs as anti-tumor agents and senolytics. R.H., G.Z. and D.Z. are cofounders of and have equity in Dialectic Therapeutics, which develops BCL-xL/2 PROTACs to treat cancer. The other authors declare no competing interests.
